November 17th, 2026Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLCThe CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.Read more
November 17th, 2026FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System LymphomaThe FDA removed the PCNSL limitation of use from the liso-cel label in LBCL, making it the second CAR T-cell therapy with this update.Read more
November 17th, 2026Quality Improvement and EGFR-Mutant Lung Cancer Survivorship Research Help Shape Fellowship TrainingChristine Ann Garcia, MD, MPH, discusses error review in fellowship training, survivorship in EGFR+ lung cancer, and nontraditional career paths.Read more
November 17th, 2026Long-Term SANO Data Reinforce Active Surveillance as an Option in Esophageal Cancer Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.Read more
November 17th, 2026Beyond the Target: Payloads, Therapeutic Windows, and Biomarkers Shape the Next Wave of ADCs in NSCLCAlissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.Read more
November 17th, 2026FDA Accepts sNDA for Selinexor Plus Ruxolitinib in MyelofibrosisThe FDA accepted an sNDA for selinexor plus ruxolitinib in myelofibrosis, with a target action date of June 28, 2027.Read more
November 17th, 2026FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLCThe FDA has approved neladalkib for previously treated, ALK-positive, locally advanced or metastatic non-small cell lung cancer.Read more
November 17th, 2026CD83 CAR T Cells Can Take the Reins When CD19 CAR T Cells Lose Their PunchRoswell Park researchers found CD83 CAR T cells could overcome CD19-targeted therapy resistance in preclinical models of B-cell cancers.Read more